http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 16 Oct 2026 03:11:01 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/William+Blair+Starts+WAVE+Life+Sciences+%28WVE%29+at+Outperform/27194809.html <p>William Blair analyst Alethia Young initiates coverage on WAVE Life Sciences (NASDAQ: WVE) with a Outperform rating.</p><p>The analyst comments: “We are initiating coverage of Wave Life Sciences with an Outperform rating, and our DCF-adjusted valuation is $8.37. Wave is a clinical-stage RNA medicines company advancing WVE-006 toward registrational development for AATD and WVE-007, an INHBE-targeting siRNA, through Phase IIa trials for obesity. Our call: We think 2027 Phase II data will better define WVE-007’s clinical profile following the Phase I dose-escalation study. We also believe WVE-006 deserves credit following FDA alignment on a pivotal study beginning in 2027. We model http://www.streetinsider.com/New+Coverage/William+Blair+Starts+WAVE+Life+Sciences+%28WVE%29+at+Outperform/27194809.html Fri, 16 Oct 2026 03:11:01 -0400 WVE http://www.streetinsider.com/Analyst+Comments/William+Blair+Starts+WAVE+Life+Sciences+%28WVE%29+at+Outperform/27194809.html <p>William Blair analyst Alethia Young initiates coverage on WAVE Life Sciences (NASDAQ: WVE) with a Outperform rating.</p><p>The analyst comments: “We are initiating coverage of Wave Life Sciences with an Outperform rating, and our DCF-adjusted valuation is $8.37. Wave is a clinical-stage RNA medicines company advancing WVE-006 toward registrational development for AATD and WVE-007, an INHBE-targeting siRNA, through Phase IIa trials for obesity. Our call: We think 2027 Phase II data will better define WVE-007’s clinical profile following the Phase I dose-escalation study. We also believe WVE-006 deserves credit following FDA alignment on a pivotal study beginning in 2027. We model http://www.streetinsider.com/Analyst+Comments/William+Blair+Starts+WAVE+Life+Sciences+%28WVE%29+at+Outperform/27194809.html Fri, 16 Oct 2026 03:11:01 -0400 WVE http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++Wave+Life+Sciences%2C+Inc.++For%3A+Dec+31/27187909.html si-local-file:///var/storage/secattach/20261014/27187909.html http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++Wave+Life+Sciences%2C+Inc.++For%3A+Dec+31/27187909.html Wed, 14 Oct 2026 17:17:00 -0400 WVE http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Wave+Life+Sciences%2C+Inc.++For%3A+Nov+12/27187886.html si-local-file:///var/storage/secattach/20261014/27187886.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Wave+Life+Sciences%2C+Inc.++For%3A+Nov+12/27187886.html Wed, 14 Oct 2026 17:15:00 -0400 WVE http://www.streetinsider.com/New+Coverage/UBS+Starts+WAVE+Life+Sciences+%28WVE%29+at+Buy/27187658.html <p>UBS initiates coverage on WAVE Life Sciences (NASDAQ: WVE) with a Buy rating and a price target of $11.00.</p> <p>For an analyst ratings summary and ratings history on WAVE Life Sciences <a href="http://www.streetinsider.com/rating_history.php?q=WVE">click here</a>. For more ratings news on WAVE Life Sciences <a href="http://www.streetinsider.com/stock_lookup_news.php?q=WVE&amp;type=analyst">click here</a>.</p> <p>Shares of WAVE Life Sciences closed at $3.14 yesterday.</p> http://www.streetinsider.com/New+Coverage/UBS+Starts+WAVE+Life+Sciences+%28WVE%29+at+Buy/27187658.html Wed, 14 Oct 2026 16:45:35 -0400 WVE http://www.streetinsider.com/Press+Releases/Wave+Life+Sciences+to+Present+at+Chardan%E2%80%99s+10th+Annual+Healthcare+Conference/27177791.html <p>CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in the “RNA Medicines: Next-Generation RNA Therapeutics” panel at Chardan’s 10^th Annual Healthcare Conference in New York City on Tuesday, October 20, 2026 at 9:45 a.m. ET.</p> <p>A live webcast of the panel can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: <a http://www.streetinsider.com/Press+Releases/Wave+Life+Sciences+to+Present+at+Chardan%E2%80%99s+10th+Annual+Healthcare+Conference/27177791.html Tue, 13 Oct 2026 08:30:00 -0400 WVE http://www.streetinsider.com/Globe+Newswire/Wave+Life+Sciences+to+Present+at+Chardan%E2%80%99s+10th+Annual+Healthcare+Conference/27177791.html <p>CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in the “RNA Medicines: Next-Generation RNA Therapeutics” panel at Chardan’s 10^th Annual Healthcare Conference in New York City on Tuesday, October 20, 2026 at 9:45 a.m. ET.</p> <p>A live webcast of the panel can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: <a http://www.streetinsider.com/Globe+Newswire/Wave+Life+Sciences+to+Present+at+Chardan%E2%80%99s+10th+Annual+Healthcare+Conference/27177791.html Tue, 13 Oct 2026 08:30:00 -0400 WVE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Wave+Life+Sciences%2C+Inc.++For%3A+Oct+05++Filed+by%3A+RA+Capital+Healthcare+Fund+LP/27162338.html si-local-file:///var/storage/secattach/20261007/27162338.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Wave+Life+Sciences%2C+Inc.++For%3A+Oct+05++Filed+by%3A+RA+Capital+Healthcare+Fund+LP/27162338.html Wed, 07 Oct 2026 21:07:00 -0400 WVE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Wave+Life+Sciences%2C+Inc.++For%3A+Oct+05++Filed+by%3A+HENRY+CHRISTIAN+O/27162329.html si-local-file:///var/storage/secattach/20261007/27162329.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Wave+Life+Sciences%2C+Inc.++For%3A+Oct+05++Filed+by%3A+HENRY+CHRISTIAN+O/27162329.html Wed, 07 Oct 2026 21:00:00 -0400 WVE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Wave+Life+Sciences%2C+Inc.++For%3A+Oct+05++Filed+by%3A+Rawcliffe+Adrian/27162330.html si-local-file:///var/storage/secattach/20261007/27162330.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Wave+Life+Sciences%2C+Inc.++For%3A+Oct+05++Filed+by%3A+Rawcliffe+Adrian/27162330.html Wed, 07 Oct 2026 21:00:00 -0400 WVE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Wave+Life+Sciences%2C+Inc.++For%3A+Oct+05++Filed+by%3A+Wagner+Heidi+L/27162331.html si-local-file:///var/storage/secattach/20261007/27162331.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Wave+Life+Sciences%2C+Inc.++For%3A+Oct+05++Filed+by%3A+Wagner+Heidi+L/27162331.html Wed, 07 Oct 2026 21:00:00 -0400 WVE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Wave+Life+Sciences%2C+Inc.++For%3A+Oct+05++Filed+by%3A+Verdine+Gregory+L./27162332.html si-local-file:///var/storage/secattach/20261007/27162332.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Wave+Life+Sciences%2C+Inc.++For%3A+Oct+05++Filed+by%3A+Verdine+Gregory+L./27162332.html Wed, 07 Oct 2026 21:00:00 -0400 WVE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Wave+Life+Sciences%2C+Inc.++For%3A+Oct+05++Filed+by%3A+TAKANASHI+KEN/27162333.html si-local-file:///var/storage/secattach/20261007/27162333.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Wave+Life+Sciences%2C+Inc.++For%3A+Oct+05++Filed+by%3A+TAKANASHI+KEN/27162333.html Wed, 07 Oct 2026 21:00:00 -0400 WVE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Wave+Life+Sciences%2C+Inc.++For%3A+Oct+05++Filed+by%3A+CORRIGAN+MARK/27162334.html si-local-file:///var/storage/secattach/20261007/27162334.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Wave+Life+Sciences%2C+Inc.++For%3A+Oct+05++Filed+by%3A+CORRIGAN+MARK/27162334.html Wed, 07 Oct 2026 21:00:00 -0400 WVE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Wave+Life+Sciences%2C+Inc.++For%3A+Oct+05++Filed+by%3A+Tan+Aik+Na/27162335.html si-local-file:///var/storage/secattach/20261007/27162335.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Wave+Life+Sciences%2C+Inc.++For%3A+Oct+05++Filed+by%3A+Tan+Aik+Na/27162335.html Wed, 07 Oct 2026 21:00:00 -0400 WVE http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+WAVE+Life+Sciences+%28WVE%29/27138733.html <p>H.C. Wainwright analyst Andrew S. Fein reiterated a Buy rating and $13.00 price target on WAVE Life Sciences (NASDAQ: WVE).</p><p>The analyst commented: "Yesterday, Wave reported FDA alignment on a single two-year registrational trial for WVE-006, with a one-year biomarker interim analysis to support potential accelerated approval. Importantly, the agency also supported the same LC-MS assay Wave has used to date. We believe this validates Wave's prior data and analyses, with the existing dataset now forms the foundation of a registrational package, and the single-trial path is capital-efficient. Additionally, management told us that the FDA engaged on the acute phase response http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+WAVE+Life+Sciences+%28WVE%29/27138733.html Fri, 02 Oct 2026 06:58:52 -0400 WVE http://www.streetinsider.com/FDA/Wave+Life+Sciences+gets+FDA+backing+for+WVE-006+registrational+trial/27131573.html <p>Wave Life Sciences (Nasdaq: WVE) announced it has received feedback from the U.S. Food and Drug Administration supporting a registrational pathway for WVE-006, its investigational RNA editing treatment for alpha-1 antitrypsin deficiency (AATD).</p> <p>Following a meeting with the FDA, the Cambridge, Mass.-based company plans to conduct a single two-year registrational trial designed to support potential full approval, with a one-year interim analysis to support potential accelerated approval based on AATD biomarkers. The FDA also indicated support for Wave's existing LC-MS assay to measure M-AAT and Z-AAT protein levels within the registrational program.</p> <p>WVE-006 is a GalNAc-conjugated, subcutaneously delivered RNA editing oligonucleotide designed http://www.streetinsider.com/FDA/Wave+Life+Sciences+gets+FDA+backing+for+WVE-006+registrational+trial/27131573.html Thu, 01 Oct 2026 07:30:24 -0400 WVE http://www.streetinsider.com/Press+Releases/Wave+Life+Sciences+Announces+FDA+Feedback+Supports+Registrational+Pathway+for+WVE-006+%28RNA+Editing%29+in+AATD/27131546.html <p><em>Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers</em></p> <p><em>WVE-006 (RNA editing) has potential to offer the AATD community a new standard-of-care treatment to protect the liver and lung with a safe and convenient therapy</em></p> <p>CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced alignment with the U.S. Food and Drug Administration (FDA) on key aspects http://www.streetinsider.com/Press+Releases/Wave+Life+Sciences+Announces+FDA+Feedback+Supports+Registrational+Pathway+for+WVE-006+%28RNA+Editing%29+in+AATD/27131546.html Thu, 01 Oct 2026 07:30:00 -0400 WVE http://www.streetinsider.com/Globe+Newswire/Wave+Life+Sciences+Announces+FDA+Feedback+Supports+Registrational+Pathway+for+WVE-006+%28RNA+Editing%29+in+AATD/27131546.html <p><em>Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers</em></p> <p><em>WVE-006 (RNA editing) has potential to offer the AATD community a new standard-of-care treatment to protect the liver and lung with a safe and convenient therapy</em></p> <p>CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced alignment with the U.S. Food and Drug Administration (FDA) on key aspects http://www.streetinsider.com/Globe+Newswire/Wave+Life+Sciences+Announces+FDA+Feedback+Supports+Registrational+Pathway+for+WVE-006+%28RNA+Editing%29+in+AATD/27131546.html Thu, 01 Oct 2026 07:30:00 -0400 WVE http://www.streetinsider.com/Corporate+News/GSK+selects+Wave+Life+Sciences+siRNA+candidate%2C+triggering+%2412M+payment/27125316.html <p>Wave Life Sciences (NASDAQ: WVE) announced that GSK has selected a siRNA candidate for a hepatology indication to transition into GSK's development pipeline, triggering a $12 million milestone payment to Wave, according to a company press release.</p><p>The selected candidate was developed using Wave's GalNAc-siRNA technology under a research collaboration between the two companies. Wave said three additional collaboration programs are continuing to advance toward potential candidate selection.</p><p>Paul Bolno, MD, MBA, commented on the selection: "The advancement of this development candidate by GSK reflects the recognition of Wave's differentiated technology, including our best-in-class SpiNA design siRNA."</p><p>Under the terms of the collaboration, http://www.streetinsider.com/Corporate+News/GSK+selects+Wave+Life+Sciences+siRNA+candidate%2C+triggering+%2412M+payment/27125316.html Wed, 30 Sep 2026 07:31:04 -0400 WVE http://www.streetinsider.com/Press+Releases/Wave+Life+Sciences+Announces+GSK%E2%80%99s+Selection+of+siRNA+program+to+Transition+to+GSK+for+Further+Development/27125280.html <p><em>Candidate selected by GSK utilizes Wave’s best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing</em></p> <p>CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that as part of the companies’ research collaboration, GSK has selected a candidate for a hepatology indication to transition into GSK’s development pipeline. This program was developed using Wave’s proprietary SpiNA design GalNAc-siRNA.</p> <p>“The advancement of this development candidate by GSK http://www.streetinsider.com/Press+Releases/Wave+Life+Sciences+Announces+GSK%E2%80%99s+Selection+of+siRNA+program+to+Transition+to+GSK+for+Further+Development/27125280.html Wed, 30 Sep 2026 07:30:00 -0400 WVE http://www.streetinsider.com/Globe+Newswire/Wave+Life+Sciences+Announces+GSK%E2%80%99s+Selection+of+siRNA+program+to+Transition+to+GSK+for+Further+Development/27125280.html <p><em>Candidate selected by GSK utilizes Wave’s best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing</em></p> <p>CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that as part of the companies’ research collaboration, GSK has selected a candidate for a hepatology indication to transition into GSK’s development pipeline. This program was developed using Wave’s proprietary SpiNA design GalNAc-siRNA.</p> <p>“The advancement of this development candidate by GSK http://www.streetinsider.com/Globe+Newswire/Wave+Life+Sciences+Announces+GSK%E2%80%99s+Selection+of+siRNA+program+to+Transition+to+GSK+for+Further+Development/27125280.html Wed, 30 Sep 2026 07:30:00 -0400 WVE http://www.streetinsider.com/FDA/Wave+Life+Sciences+starts+Phase+2a+combo+trial+of+WVE-007+with+tirzepatide/27093331.html <p>Wave Life Sciences Ltd. (Nasdaq: WVE) announced the initiation of a Phase 2a clinical trial evaluating WVE-007, an investigational GalNAc-siRNA targeting INHBE, in combination with tirzepatide in adults living with obesity, according to a company press release.</p> <p>The placebo-controlled trial, conducted at a 3:1 ratio, will evaluate 240 mg and 400 mg doses of WVE-007 combined with weekly tirzepatide in individuals with a BMI of 35–50 kg/m² and type 2 diabetes.</p> <p>The trial is part of Wave's INLIGHT™ clinical program, which also includes an ongoing Phase 2a monotherapy trial with multiple assessments over a 12-month period. Results from the monotherapy trial are http://www.streetinsider.com/FDA/Wave+Life+Sciences+starts+Phase+2a+combo+trial+of+WVE-007+with+tirzepatide/27093331.html Wed, 23 Sep 2026 07:30:12 -0400 WVE http://www.streetinsider.com/Press+Releases/Wave+Life+Sciences+Initiates+Phase+2a+Combination+Trial+of+WVE-007+%28GalNAc-siRNA%29+with+Tirzepatide+for+Obesity/27093313.html <p><em>WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave’s INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss compared with GLP-1 alone </em></p> <p><em>Maintenance clinical trial evaluating WVE-007’s ability to curtail weight regain after incretin cessation on track to initiate 2H 2026</em></p> <p>CAMBRIDGE, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the initiation of its Phase 2a clinical trial evaluating WVE-007, an investigational GalNAc-siRNA, http://www.streetinsider.com/Press+Releases/Wave+Life+Sciences+Initiates+Phase+2a+Combination+Trial+of+WVE-007+%28GalNAc-siRNA%29+with+Tirzepatide+for+Obesity/27093313.html Wed, 23 Sep 2026 07:30:00 -0400 WVE http://www.streetinsider.com/Globe+Newswire/Wave+Life+Sciences+Initiates+Phase+2a+Combination+Trial+of+WVE-007+%28GalNAc-siRNA%29+with+Tirzepatide+for+Obesity/27093313.html <p><em>WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave’s INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss compared with GLP-1 alone </em></p> <p><em>Maintenance clinical trial evaluating WVE-007’s ability to curtail weight regain after incretin cessation on track to initiate 2H 2026</em></p> <p>CAMBRIDGE, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the initiation of its Phase 2a clinical trial evaluating WVE-007, an investigational GalNAc-siRNA, http://www.streetinsider.com/Globe+Newswire/Wave+Life+Sciences+Initiates+Phase+2a+Combination+Trial+of+WVE-007+%28GalNAc-siRNA%29+with+Tirzepatide+for+Obesity/27093313.html Wed, 23 Sep 2026 07:30:00 -0400 WVE